DDIT3 and heart failure: In the remaining 54 patients, there was no difference in the incidence of decreased LVEF between treatment groups (CEpOP+/−R=27/180, 15.0% vs. CHOP+/−R=27/168, 16.1%, P = 0.783), and these patients did not develop symptoms of heart failure during the study.